Resistance and progression mechanisms in prostate cancer
PRINCIPAL INVESTIGATORS
- Mireia Olivan Riera
CLINICAL RESEARCHERS
- Maria Pane Foix
- Manuel Maria Castells Esteve
- Jose Francisco Suarez Novo
- Natàlia Picola Brau
POSTDOCTORAL RESEARCHERS
- Adrian Martinez Tébar
- Ana Sofia Semiao Correia Da Rocha
- Rana El Bizri
PREDOCTORAL RESEARCHERS
- Nadia García Lozano
- Mireia Olivan Riera
- Pilar Salamanca Jimenez
- Javier Sigüenza Andrade
Cancer
Oncobell
Scientific production
13
PAPERS
Average IF: 5,47
4
LED PAPERS
Average IF: 10,1
2 PUBLICATIONS IN FIRST DECILE
10 PUBLICATIONS IN FIRST QUARTILE
10 PUBLICATIONS IN FIRST QUARTILE
Selected publications
- Vigués,F;Etcheverry,B;Reggeti,J;Gaya,JM;Territo,A;Gallioli,A;Berquin,C et al, Orthotopic Robot-assisted Kidney Transplantation: Surgical Technique and Preliminary Results, Eur Urol, 2024;85(6):556-564, doi:10.1016/j.eururo.2024.03.037
- Hu,HB;Serra,C;Zhang,WJ;Scrivo,A;Fernández Carasa,I;Consiglio,A;Aytes,A et al, Identification of differential biological activity and synergy between the PARP inhibitor rucaparib and its major metabolite, Cell Chem Biol, 2024;31(5):doi:10.1016/j.chembiol.2024.01.007
- Sanz Serra,P;Etcheverry,B;Fiol,M;Fábregas,M;Lozano,V;Pérez Reggeti,JI;Buisan,Ó et al, Robotic Repair of Ureteral Strictures After Kidney Transplantation., Transplantation, 2024;doi:10.1097/TP.0000000000005237,
- Morote,J;Picola,N;Muñoz Rodriguez,J;Paesano,N;Ruiz Plazas,X;Muñoz Rivero,MV;Celma,A et al, Effect of 5-Alpha Reductase Inhibitors on Magnetic Resonance Imaging and Prostate Cancer Detection, Biomolecules, 2024;14(2):doi:10.3390/biom14020193,
- Morote,J;Paesano,N;Picola,N;Miró,B;Abascal,JM;Servian,P;Trilla,E et al, Comparing Two Targeted Biopsy Schemes for Detecting Clinically Significant Prostate Cancer in Magnetic Resonance Index Lesions: Two- to Four-Core versus Saturated Transperineal Targeted Biopsy, Cancers, 2024;16(13):doi:10.3390/cancers16132306
Research highlights
PROJECTS
3 Granted competitive projects
10 Ongoing competitive projects
2 Started clinical trials
5 Ongoing clinical trials
1 Ongoing non competitive project
NETWORKS
AGAUR – SGR
Selected projects
- PC210340. Dissecting the role of cancer cell chromatin remodeling on the landscape of tumor immune microenvironment. DEPARTMENT OF DEFENSE. Budget: 465.431,26€. 2022-2025. PI: AYTES MENESES, ALVARO.
- LABAE211710AYTE. Dissecting EZH2-SWI/SNF antagonism to target cell plasticity in therapy resistant prostate cancer. Asociación Española Contra el Cáncer (AECC). Budget: 299.363,42€. 2021-2025. PI: AYTES MENESES, ALVARO.
- PI19/00342. Therapeutic landscape and predictive biomarkers for DNA damage repair pathway inhibitors in advanced prostate cancer. Instituto de Salud Carlos III (ISCIII). Budget: 255.310€. 2020-2024. PI: AYTES MENESES, ALVARO.
- PI23/00513. Inhibición de la señalización mediada por ROS para superar la resitencia a antiandrógenos e immunoterápia en cáncer de próstata resistente a la castración. Instituto de Salud Carlos III (ISCIII). Budget: 233.750€. 2024-2026. PI: AYTES MENESES, ALVARO.
- CNS2023-145615/CNS2023-145615_1/CNS2023-145615_2. Impacto del pérdida de Brca2 en la plasticidad de linaje y la resistencia a la castración en cáncer de próstata. Ministerio de Ciencia e Innovación. Budget: 199.922€. 2024-2026. PI: AYTES MENESES, ALVARO.